These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8882543)
1. Management of hyperlipidaemia: postscript. Sum CF; Tan CE; Chew LS Singapore Med J; 1995 Oct; 36(5):538. PubMed ID: 8882543 [No Abstract] [Full Text] [Related]
2. Pharmacological treatment for hyperlipidaemia--the best preventive measure? Rosengren A; Swedberg K Eur Heart J; 1999 Feb; 20(4):245-6. PubMed ID: 10099914 [No Abstract] [Full Text] [Related]
6. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed. Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409 [No Abstract] [Full Text] [Related]
7. Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):1Q-2Q. PubMed ID: 9819097 [No Abstract] [Full Text] [Related]
8. Dyslipidemia and coronary heart disease: management issues from Indian perspective. Gambhir DS; Gambhir JK; Sudha R Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772 [No Abstract] [Full Text] [Related]
9. Lipids and their role in coronary heart disease: what they do and how to manage them. Pradka LR Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283 [TBL] [Abstract][Full Text] [Related]
11. Improvement in current approaches to lipid lowering. Ansell BJ Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952 [No Abstract] [Full Text] [Related]
12. [Analysis of reasons for discontinuation of treatment for dyslipidemia in secondary prevention of coronary heart disease]. Tyszecka G Przegl Lek; 1999; 56(11):709-15. PubMed ID: 10800583 [TBL] [Abstract][Full Text] [Related]
13. Current drug treatments for lipid management. Stone NJ Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341 [No Abstract] [Full Text] [Related]
14. Management of patients with dyslipidaemia. Mann J; Chisholm A; Crooke M; Jackson R; Neutze J; North D; Swinburn B; White H; Wilcox J N Z Med J; 1995 Oct; 108(1010):444. PubMed ID: 7478355 [No Abstract] [Full Text] [Related]
16. [Role of lipemia-lowering agents in the secondary prevention of myocardial infarct]. Tullio D Clin Ter; 1986 Feb; 116(3):221-35. PubMed ID: 3516543 [No Abstract] [Full Text] [Related]
17. Choosing the most appropriate therapy for lipid disorders. Simons LA Aust Fam Physician; 2000 Mar; 29(3):199-203. PubMed ID: 10785984 [TBL] [Abstract][Full Text] [Related]
18. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)? Sherrod JP; Krist A J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006 [No Abstract] [Full Text] [Related]
19. [Sulodexide in the therapy of vasculopathies]. Postiglione F; Pisani P; Gisonni P; Perrotta P; Gisonni A; Canciello M; Napolitano L; Brighina G; Ragno I; Salzano A Clin Ter; 1986 May; 117(3):223-31. PubMed ID: 3524974 [No Abstract] [Full Text] [Related]
20. Aggressive medical therapy for the prevention and treatment of coronary artery disease. Malloy MJ; Kane JP Adv Intern Med; 1997; 42():1-38. PubMed ID: 9048115 [No Abstract] [Full Text] [Related] [Next] [New Search]